Literature DB >> 6355391

Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs.

H W Smith, M B Huggins.   

Abstract

A mixture of two phages, B44/1 and B44/2, protected calves against a potentially lethal oral infection with an O9:K30,99 enteropathogenic strain of Escherichia coli, called B44, when given before, but not after, the onset of diarrhoea; a mixture in which phage B44/3 was replaced by phage B44/3 was effective after the onset of diarrhoea. Calves that responded to phage treatment had much lower numbers of E. coli B44 in their alimentary tract than untreated calves. Usually, high numbers of phage B44/1 and rather lower numbers of phage B44/2 or B44/3 were present in the alimentary tract of these animals. At death, most calves that had not responded to treatment with phages B44/1 and B44/2 had high numbers of mutants of E. coli B44 resistant to phage B44/1 in their small intestine. Phage-treated calves that survived E. coli infection continued to excrete phage in their faeces, at least until the numbers of E. coli B44 also excreted were low. The phages survived longer than E. coli B44 in faecal samples taken from phage-treated calves and exposed to the atmosphere in an unheated animal house. Calves inoculated orally with faecal samples from phage-treated calves that contained sufficient E. coli B44 to cause a lethal infection remained healthy. A mixture of two phages, P433/1 and P433/2, and phage P433/1 alone cured diarrhoea in piglets caused by an O20:K101,987P strain of E. coli called P433. The numbers of the infecting bacteria and phages in the alimentary tract of the piglets resembled those in the calves. Another phage given to lambs 8 h after they were infected with an O8:K85,99 enteropathogenic strain of E. coli, called S13, reduced the numbers of these organisms in the alimentary tract and had an ameliorating effect on the course of the disease. No phage-resistant mutants of E. coli S13 were isolated from the lambs. The only mutants of E. coli B44 and P433 that emerged in the calves and piglets were K30- or K101- and resistant to phage B44/1 or P433/1 respectively; those tested were much less virulent than their parent strains.

Entities:  

Mesh:

Year:  1983        PMID: 6355391     DOI: 10.1099/00221287-129-8-2659

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  91 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 3.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Reviving Phage Therapy for the Treatment of Cholera.

Authors:  Sudhakar Bhandare; Joan Colom; Abiyad Baig; Jenny M Ritchie; Habib Bukhari; Muhammad A Shah; Banwarilal L Sarkar; Jingliang Su; Brendan Wren; Paul Barrow; Robert J Atterbury
Journal:  J Infect Dis       Date:  2019-02-15       Impact factor: 5.226

5.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

6.  Impact of phages on two-species bacterial communities.

Authors:  W R Harcombe; J J Bull
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

7.  Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle.

Authors:  J J Gill; J C Pacan; M E Carson; K E Leslie; M W Griffiths; P M Sabour
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 8.  Bacteriophage therapy against Enterobacteriaceae.

Authors:  Youqiang Xu; Yong Liu; Yang Liu; Jiangsen Pei; Su Yao; Chi Cheng
Journal:  Virol Sin       Date:  2015-02-03       Impact factor: 4.327

9.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

10.  Exploiting the role of TolC in pathogenicity: identification of a bacteriophage for eradication of Salmonella serovars from poultry.

Authors:  Vito Ricci; Laura J V Piddock
Journal:  Appl Environ Microbiol       Date:  2010-01-15       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.